Transplant recipients who smoke or have smoked increase their risk of viral hepatitis reinfection following liver transplantation according to new research available in the July issue of Liver Transplantation, a journal published by Wiley on behalf of American Association for the Study of Liver Diseases. Findings suggest that tobacco in cigarettes may adversely affect immune system response in patients transplanted for viral hepatitis.
According to the Centers for Disease Control and Prevention (CDC), tobacco use causes more than five million deaths per year worldwide, with estimates suggesting that annual mortality rates could climb to more than eight million by 2030. Previous research reports that nearly 34% of liver transplant recipients are active or former tobacco users. Moreover, medical evidence has shown that smoking increased biliary and vascular complications in the short-term, and elevated risk of all-cause, cardiovascular and sepsis-related mortality in the long-term among those receiving livers.
"Organs available for transplantation are scarce, with livers particularly in short supply," explains Dr. Mamatha Bhat from McGill University in Canada. "Transplant centers need to take an active role in identifying and minimizing risks to the success of liver transplantation." In the present study, researchers assessed the impact of smoking on incidence of complications, such as recurrent viral hepatitis, following liver transplantation.
Analysis of demographic characteristics and post-transplantation complications was performed on data from primary liver transplant recipients over a 14-year period. Using data from the McGill University Health Centre (MUHC) Liver Transplant database, the team identified 444 patients who received liver transplants between 1990 and 2004, of which 63 were repeat transplants. The mean age of liver recipients was 55 years and 66% were male with a mean body mass index (BMI) of 27.
Results show that 23% of transplant recipients were active or ex-smokers and 78% were non-smokers. Of those who ever smoked, 78% were male and 88% were Caucasian. The cause of liver disease was likely to be alcohol related in 29% of smokers or ex-smokers compared to 16% non-smokers. Researchers estimated the median survival time for smokers following transplantation was just over 13 years.
Further analysis shows that the recurrent viral hepatitis-free survival time was less than one year for smokers and close to five years for non-smokers. The team found that patient survival, and time to biliary complications, first rejection and depression post-transplantation was not linked to smoking status. However, recurrent viral hepatitis-free survival was strongly associated with smoking.
"Our findings suggest that recurrence of viral hepatitis may be more frequent among liver transplant recipients who are active or former smokers," concludes Dr. Bhat. "Encouraging preoperative smoking cessation may be beneficial in improving patient outcomes following transplantation." The authors stress that their findings do not suggest the denial of liver transplantation, but that transplant specialists be more vigilant in monitoring for complications in those candidates who continue to smoke. They call for validation of their results in larger studies that examine the effects of smoking and other potential modifiable risks.
This study is published in Liver Transplantation. Media wishing to receive a PDF of this article may contact firstname.lastname@example.org.
Full citation: "Smoking Increases Recurrent Viral Hepatitis After Liver Transplantation." Mamatha Bhat, Marc Deschenes, Xianming Tan, Myriam Martel, Venkataramana Bhat, Philip Wong, Peter Metrakos, Peter Ghali. Liver Transplantation; Published Online: March 30, 2012 (DOI: 10.1002/lt.23444) Print Issue Date: July 2012. URL: http://onlinelibrary.wiley.com/doi/10.1002/lt.23444/abstract
About the Author: Dr. Peter Ghali, senior study author, is with the division of gastroenterology at Royal Victoria Hospital.
To arrange an interview with the senior author, Dr. Peter Ghali, or with Dr. Bhat, please contact Julie Robert with McGill University Health Centre at email@example.com or at 514 934-1934 ext. 71381.
About the Journal:
Liver Transplantation is published by Wiley on behalf of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. Since the first application of liver transplantation in a clinical situation was reported more than twenty years ago, there has been a great deal of growth in this field and more is anticipated. As an official publication of the AASLD and the ILTS, Liver Transplantation delivers current, peer-reviewed articles on surgical techniques, clinical investigations and drug research — the information necessary to keep abreast of this evolving specialty. For more information, please visit Liver Transplantation.
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.
Our core businesses publish scientific, technical, medical, and scholarly journals, encyclopedias, books, and online products and services; professional/trade books, subscription products, training materials, and online applications and Web sites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.